 Tiziana Life Sciences PLC NASDAQ:TLSA, LON:TILS said it has inked an exclusive licensing agreement with Precision BioSciences NASDAQ:DTIL to explore the use of Tizianas foralumab monoclonal antibody mAb to enhance the next generation of CAR-T therapies. CAR-T, or chimeric antigen receptors cell therapy, is at the vanguard of treating blood-borne cancers, and major acquisitions by Celgene now owned by Bristol Myers Squibb and Gilead Sciences NASDAQ:GILD underscore the interest in this emerging area of biotechnology. 